Skip to content
Kabra Drugs logo

Kabra Drugs

524322 BSE
Price unavailable

Kabra Drugs (KABRADG) share price was ₹16.26 at the 28 Oct 2026 close; market capitalisation ₹38.52 Cr; P/E (TTM) 5.08; sector Healthcare. The share price fell 15.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 546.4% year on year to ₹46.22 Cr and net profit was ₹2.12 Cr, against −₹0.50 Cr a year earlier (compared with Jun 2025). Promoters held 0.00% of Kabra Drugs in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 49/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹16.26 −3.26 −16.70% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹38.52 Cr
P/E (TTM)
5.08
EBITDA
₹5.80 Cr
Return on Equity
16.75%
Debt to Equity
0.03
Book Value
₹12.49
EPS (TTM)
₹3.20
52W High
₹35.52
52W Low
₹15.30

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.5035.044,23,843 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,635.0087.452,55,779 Cr15.260.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,598.4072.191,74,908 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,184.70107.941,18,042 Cr22.270.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.5026.271,17,755 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,341.0034.731,11,931 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.5032.831,10,717 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Kabra Drugs (this company)
—5.0839 Cr1.300.00%16.75%19.34%132 Cr8 Cr
Median 8 companies₹1,766.5034.891,17,899 Cr4.710.47%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

49 Average
Overall score

Data confidence 95/100

Category scores

Quality Poor 29
Returns, margins, earnings quality 22% weight
Valuation Good 63
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Average 48
Solvency, leverage, coverage 9% weight
Momentum Poor 8
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has delivered good profit growth of 96.8% CAGR over last 5 years

Weaknesses

2
  • Company has a low return on equity of 7.79% over last 3 years.
  • Company has high debtors of 279 days.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
12
Neutral
6
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
—

Net Income Growth
-555% lower than 3Y

change over 1 year

Cash Flow Change
-101%

change over 1 year

EBITDA Margin Change
-104%

change over 1 year Operating margin 6.04% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
7.15
19.76
30.42
35.41
46.22
Expenses
0.12
0.13
0.11
0.37
0.55
0.4
0.53
0.24
7.67
17.72
27.99
34.07
43.43
Operating Profit
-0.12
-0.13
-0.11
-0.37
-0.55
-0.4
-0.53
-0.24
-0.52
2.04
2.43
1.34
2.79
OPM %
—
—
—
—
—
—
—
—
-7.27%
10.32%
7.99%
3.78%
6.04%
Other Income
0
0
0
0
0
0
0
0.64
0.02
0.18
0.18
0.11
0.08
Interest
0
0
0
0
0
0
0
0
0
0
0
0.01
0.01
Depreciation
0
0
0
0
0
0
0
0.01
0
0.01
0.01
0.02
0.02
PBT
-0.12
-0.13
-0.11
-0.37
-0.55
-0.4
-0.53
0.39
-0.5
2.21
2.6
1.42
2.84
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
16.74%
1.54%
25.35%
25.35%
Net Profit
-0.12
-0.13
-0.11
-0.37
-0.55
-0.4
-0.54
0.39
-0.5
1.84
2.57
1.06
2.12
EPS (₹)
-0.27
-0.3
-0.25
-0.84
-1.25
-0.4
-0.54
0.16
-0.21
0.78
1.08
0.45
0.89
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8
10
8
2
0
0
0
0
0
0
0
93
132
Expenses
8
9
7
3
0
0
0
0
0
1
2
87
123
Operating Profit
0
0
0
-1
0
0
0
0
0
-1
-2
5
9
OPM %
6%
4.7%
6%
-57%
—
-150%
—
—
-3400%
—
—
6%
7%
Other Income
0
0
0
-1
0
0
0
0
0
0
1
0
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
-2
0
0
0
0
0
-1
-1
6
9
Tax %
36%
40%
7%
0%
0%
0%
0%
0%
0%
0%
0%
13%
—
Net Profit
0
0
0
-2
0
0
0
0
0
-1
-1
5
8
EPS (₹)
0.16
0.07
0.3
-5.38
-0.36
-0.14
-0.41
-0.43
-0.77
-1.69
-0.46
2.09
3.2
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
4
4
4
4
4
4
4
4
4
24
24
Reserves
-2
-2
-2
-4
-4
-4
-5
-5
-5
-3
1
6
Borrowings
3
2
2
1
1
1
1
1
1
2
0
1
Other Liabilities
3
4
2
1
1
1
1
0
0
2
0
56
Total Liabilities
9
9
6
2
1
1
1
1
1
5
25
86
Fixed Assets
3
3
2
0
0
0
0
0
0
0
0
1
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
6
6
4
2
1
1
1
1
1
5
25
85
Total Assets
9
9
6
2
1
1
1
1
1
5
25
86
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
0
0
0
0
0
0
0
0
0
-5
-9
Investing
0
0
0
2
0
0
0
0
0
0
0
-1
Financing
1
0
0
-1
0
0
0
0
0
3
23
0
Net Cash Flow
0
0
0
0
0
0
0
0
0
3
19
-11
Free Cash Flow
0
0
0
1
0
0
0
0
0
0
-5
-10
CFO/OP
-38
67
73
10
138
100
167
72
100
28
274
-173
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
198
204
141
254
—
—
—
—
—
—
—
279
Inventory Days
26
16
17
0
—
—
—
—
—
—
—
0
Days Payable
130
140
97
—
—
—
—
—
—
—
—
—
Cash Conversion Cycle
94
80
61
254
—
—
—
—
—
—
—
279
Working Capital Days
86
70
34
-28
—
—
—
—
—
—
—
66
ROCE %
4%
4%
7%
-44%
-19%
-9%
-27%
-29%
-53%
-43%
-8%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kabra Drugs insights

61 extracted metrics + investor summaries across FY07–FY27.

Shareholding Pattern

Public90.88%Others9.12%As ofSep 2026

Documents

Frequently Asked Questions about Kabra Drugs

What does Kabra Drugs Ltd do?
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]
Where is Kabra Drugs Ltd (KABRADG) listed?
Kabra Drugs Ltd trades under code 524322 on the BSE.
Which sector does Kabra Drugs Ltd belong to?
Kabra Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Kabra Drugs Ltd?
Kabra Drugs Ltd has a market capitalisation of ₹38.52 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd trades at a PE ratio of 5.08 as of 28 Oct 2026, on earnings per share of ₹3.2, against a book value of ₹12.49 per share.
What is the 52-week high and low of Kabra Drugs Ltd?
Over the last 52 weeks Kabra Drugs Ltd has traded between ₹15.3 and ₹35.52 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Kabra Drugs Ltd?
Kabra Drugs Ltd reported a return on equity of 16.75%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]

Website kabradrugs.com
Face Value ₹ 10
Shares Outstanding 2,36,87,351

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524322.md for Kabra Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month